Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Composite personalized care for functional outcome in early psychosis
2022-001244-15Phase 3Active
- Sponsor
- GHU Paris psychiatrie & neurosciences
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cyanocobalamin, folinic acid, acetylcysteine and eicosapentaenoic acid + docosahexaenoic acid in psychosis and Clinical high risk for psychosis (CHR) (4 arms), sponsored by GHU Paris psychiatrie & neurosciences. Primary endpoint: Global functioning at 3 to 4 months. Started Oct 2022; status: active.
02
Drugs
cyanocobalaminfolinic acidacetylcysteineeicosapentaenoic acid + docosahexaenoic acid
03
Conditions
psychosisClinical high risk for psychosis (CHR)
Beyond the preview
Go deeper on 2022-001244-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001244-15.